Truist cuts Regeneron stock price target on FDA approval delay By Investing.com

Regeneron reported Q1 2026 EPS of $9.47 versus $8.97 expected and revenue of $3.6B versus $3.48B expected, but Truist cut its price target to $769 from $801 while keeping a Buy rating. The note flagged continued concerns over FDA inaction on Eylea HD prefilled syringe approval, even as Dupixent remained strong and the pipeline expanded. Shares traded at $686.66, and analysts cited the next catalyst as LAG-3 topline data in Q2 2026.

Analysis

REGN is in the awkward middle stage of a biotech rerating: earnings quality is good enough to prevent a full de-rate, but not strong enough to command a scarcity premium. The market is signaling that Dupixent can keep the base business resilient, yet the stock needs a new incremental value driver because the next leg of upside is no longer coming from multiple expansion on stable cash flows alone.

The real issue is not the quarter; it is franchise concentration risk. If the eye franchise continues to lose mix or regulatory cadence slips further, the market will start capitalizing REGN more like a mature cash-generative pharma asset than a growth biotech, which would compress the multiple even if EPS keeps beating. That makes the second-order question whether pipeline readouts can be large enough to offset a slowing U.S. ophthalmology flywheel within the next 2-3 quarters.

Consensus appears to be underestimating how quickly sentiment can improve if the LAG-3 dataset is even modestly positive, because the stock is now pricing in a fairly high bar for follow-through assets. Conversely, the downside is cushioned by current earnings power, so this is less a single-event binary and more a catalyst-stack trade over the next 6-9 months. The best risk/reward is likely not outright long-beta biotech, but owning REGN only on technical weakness or pairing it against lower-quality large-cap biotech names with less visible cash generation.

Key Decisions for Investors

• Buy REGN on a 3-5% post-event pullback, targeting the next 2-3 quarter catalyst window; risk/reward improves because the stock is supported by earnings power while upside depends on a single incremental readout.
• Use REGN Dec/Mar call spreads rather than stock if positioning for LAG-3 data; the implied move is likely too low for a positive readout but outright upside is capped by the market's 'show me' stance.
• Pair long REGN vs short a lower-quality large-cap biotech with weaker pipeline visibility over the next 6 months; REGN has better cash flow durability and less balance-sheet/catalyst fragility.
• If Eylea-related weakness persists into the next quarter, reduce exposure into strength; that signal would shift the market narrative from temporary friction to structural franchise decay.
• Do not chase here on momentum alone; wait for either data de-risking or a wider sector selloff, since the stock needs a new catalyst to justify multiple expansion.